MedDataX Logo

To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema

NCT ID: NCT00371111

Last Updated: 2008-07-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-08-31

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cystoid macular edema (CME) is one of the common causes of vision loss in patients with UveitiS .Triamcinolone has been effectively used in reducing CME and improving the vision. Also there are some documents which recommend Bevacizumab(avastin) could reduce macular edema. This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Resistant Cystoid Macular Edema

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Resistant uveitic cystoid macular edema intravitreal triamcinolone intravitreal bevacizumab

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Intravitreal injection of Triamcinolone

Group Type ACTIVE_COMPARATOR

Intravitreal injection of Triamcinolone

Intervention Type DRUG

4 mg of Triamcinolone

2

Intravitreal injection of Avastin

Group Type ACTIVE_COMPARATOR

Intravitreal injection of Avastin

Intervention Type DRUG

Injection of 1.25 mg of Avastin and

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intravitreal injection of Triamcinolone

4 mg of Triamcinolone

Intervention Type DRUG

Intravitreal injection of Avastin

Injection of 1.25 mg of Avastin and

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Uveitic CME
* Uveitic CME refractory to routine treatment
* Vision better than 5/200 and worse than 20/50

Exclusion Criteria

* Mono- Ocular patients
* History of vitrectomy
* Glaucoma or ocular hypertension
* History of other retinal disease that can cause macular edema
* Pregnancy
* Significant media opacity
* Vision better than 20/50
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shahid Beheshti University of Medical Sciences

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Masoud Soheilian, MD

Role: PRINCIPAL_INVESTIGATOR

Ophthalmic Research Center of Shaheed Beheshti Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Masoud Soheilian , MD

Tehran, Tehran Province, Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

8524

Identifier Type: -

Identifier Source: org_study_id